

- Sub 1*
- Sub 2*
- Sub 3*
- Sub 4*
- Sub 5*
- Sub 6*
- Sub 7*
- Sub 8*
- Sub 9*
- Sub 10*
- Sub 11*
- Sub 12*
- Sub 13*
- Sub 14*
- Sub 15*
- Sub 16*
- Sub 17*
- Sub 18*
- Sub 19*
- Sub 20*
- Sub 21*
- Sub 22*
- Sub 23*
- Sub 24*
- Sub 25*
5. (Once amended) The method of claim 1 [any one of the preceding claims] wherein the growth factor is expressed as a fusion with a viral envelope protein and is attached to the N-terminus of a retroviral envelope protein.
6. (Once amended) The method of claim 5 [any one of the preceding claims] wherein the growth factor is expressed as a fusion with a viral envelope protein and is fused to the envelope protein via a cleavable linker.
7. (Once amended) The method of claim 1 [any one of the preceding claims] wherein the envelope protein is viral envelope SU protein.
8. (Once amended) The method of claim 1 [any one of the preceding claims] wherein the retroviral packaging cell line further expresses nucleic acid encoding a receptor to target the cells to the bone marrow and/or an immunosuppressive factor so that the receptor and/or immunosuppressive factor are displayed on the cell surface.
9. (Once amended) A population of cells produced by the method of claim 1 [any one of claims 1 to 8] having the nucleic acid encoding a polypeptide for treating a disease or disorder stably incorporated into their genome.
11. (Once amended) A method of treating a patient comprising administering to the patient an effective amount of the [Use of the] cells of claim 9 [in the preparation of a medicament for the treatment of a disease or disorder in a patient that responds to the polypeptide].
12. (Once amended) The method [use] of claim 11 wherein the cells are administered by implantation into the patient.
15. (Once amended) The retroviral packaging cell line of claim 13 [or claim 14] wherein the growth factor is stem cell factor (SCF) or FLT3 ligand.
16. (Once amended) The retroviral packaging cell line of claim 13 [any one of claims 13 to 16] wherein the cell line displays multiple growth factors.

a/cnt.

1 17. (Once amended) The retroviral packaging cell line of claim 13 [any one of claims 13
2 to 16] wherein the cell line is a lentiviral packaging cell line.

3 18. (Once amended) The retroviral packaging cell line of claim 13 which further
4 expresses [any one of the claims 13 to 17, further expressing] nucleic acid encoding a receptor to
5 target the cells to the bone marrow and/or an immunosuppressive factor so that the receptor and/or
6 immunosuppressive factor are displayed on the cell surface.

7 19. (Once amended) A pharmaceutical composition comprising the retroviral packaging
8 cell line of claim 13 [any one of claims 13 to 18], in combination with a pharmaceutically acceptable
9 carrier.

10 20. (Once amended) A method of treating a patient comprising administering to the
11 patient an effective amount of [Use of] the retroviral packaging cell line of claim 13 [claims 13 to 18
12 in the preparation of a medicament for treating a disease or disorder that responds to the
13 polypeptide].

14 21. (Once amended) The method [use] of claim 20 wherein the retroviral packaging cell
15 line is administered by implantation into a patient's bone marrow or by infusion into a patient's
16 blood.
17 ///
18 ///
19 ///
20 ///
21 ///
22 ///
23 ///
24 ///
25 ///